Skip to main content
. 2006 Aug 22;66(2):235–241. doi: 10.1136/ard.2006.057133

Table 2 Summary of reasons for discontinuation of treatment in phase II (6–18 months).

Combination group SASP alone MTX alone
Intercurrent illness 1
Side effects 12 10 14
Lack of effect 2 4 2
Non‐compliance/lost to follow‐up 2
Total 17 14 16

MTX, methotrexate; SASP, sulfasalazine.